SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Gorman JD, Danning C, Schumacher HR, Klippel JH, Davis JC Jr. Multicentric reticulohistiocytosis: case report with immunohistochemical analysis and literature review. Arthritis Rheum 2000; 43: 9308.
  • 2
    Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973; 3: 5578.
  • 3
    Yoshida M, Belt EA, Kaarela K, Kauppi MJ, Shimamura T. Prevalence of mutilans-like hand deformities in patients with seropositive rheumatoid arthritis: a prospective 20-year study. Scand J Rheumatol 1999; 28: 3840.
  • 4
    Liu YH, Fang K. Multicentric reticulohistiocytosis with generalized systemic involvement. Clin Exp Dermatol 2004; 29: 3736.
  • 5
    Adamopoulos IE, Wordsworth PB, Edwards JR, Ferguson DJ, Athanasou NA. Osteoclast differentiation and bone resorption in multicentric reticulohistiocytosis. Hum Pathol 2006; 37: 117685.
  • 6
    Goto H, Inaba M, Kobayashi K, Imanishi Y, Kumeda Y, Inui K, et al. Successful treatment of multicentric reticulohistiocytosis with alendronate: evidence for a direct effect bisphosphonate on histiocytes. Arthritis Rheum 2003; 48: 353841.
  • 7
    Mavragani CP, Batziou K, Aroni K, Pikazis D, Manoussakis MN. Alleviation of polyarticular syndrome in multicentric reticulohistiocytosis with intravenous zoledronate [letter]. Ann Rheum Dis, 2005; 64: 15212.
  • 8
    Vieira R, Cordeiro MR, Mariano A, Reis JP. Multiple cutaneous reticulohistiocytomas in a patient with rheumatoid arthritis. Dermatol Online J 2004; 10: 11.
  • 9
    Gravallese EM, Goldring SR. Cellular mechanisms and the role of cytokines in bone erosions in rheumatoid arthritis [review]. Arthritis Rheum 2000; 43: 214351.
  • 10
    Martini G, Gennari L, Merlotti D, Salvadori S, Franci MB, Campagna S, et al. Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget's disease of bone. Bone 2007; 40: 45763.
  • 11
    Pysklywec MW, Moran EL, Bogoch ER. Zoledronate (CGP 42'446), a bisphosphonate, protects against metaphyseal intracortical defects in experimental inflammatory arthritis. J Orthop Res 1997; 15: 85861.
  • 12
    Jarrett SJ, Conaghan PG, Sloan VS, Papanastasiou P, Ortmann CE, O'Connor PJ, et al. Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis. Arthritis Rheum 2006; 54: 14104.
  • 13
    Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci U S A 1999; 96: 1338.
  • 14
    Runger TM, Quintanilla-Dieck MJ, Bhawan J. Role of cathepsin K in the turnover of the dermal extracellular matrix during scar formation. J Invest Dermatol 2007; 127: 2937.
  • 15
    Hummel KM, Petrow PK, Franz JK, Muller-Ladner U, Aicher WK, Gay RE, et al. Cysteine proteinase cathepsin K mRNA is expressed in synovium of patients with rheumatoid arthritis and is detected at sites of synovial bone destruction. J Rheumatol 1998; 25: 188794.
  • 16
    Morko J, Kiviranta R, Joronen K, Saamanen AM, Vuorio E, Salminen-Mankonen H. Spontaneous development of synovitis and cartilage degeneration in transgenic mice overexpressing cathepsin K. Arthritis Rheum 2005; 52: 37137.